Evidence map›Paper›PMID 41282267›Full record

ArticleResearch square2025

A Split Biotin Ligase Approach to Revealing Proteins Associated with Oligomeric Alpha-Synuclein During Aggregation.

Analiese R Fernandes, Abigail P Owen, Ayman H Faroqi, Jannifer Lee, Gunveen S Sachdeva, Dmytro Morderer, Cody Hoffmann, Benjamin Madden, Shuwen Zhang, Yingxue Ren and 4 more

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Analiese R FernandesMayo Clinic Graduate School of Biomedical Sciences.
Abigail P OwenMayo Clinic Office for Non-Clinical Education Programs.
Ayman H FaroqiMayo Clinic Graduate School of Biomedical Sciences.
Jannifer LeeMayo Clinic Department of Neuroscience.
Gunveen S SachdevaMayo Clinic.
Dmytro MordererMayo Clinic Department of Neuroscience.
Cody HoffmannMayo Clinic.
Benjamin MaddenMayo Clinic.
Shuwen ZhangMayo Clinic.
Yingxue RenMayo Clinic Department of Quantitative Health Sciences.
Suelen L BoschenMayo Clinic Department of Neuroscience.
Akhilesh PandeyMayo Clinic.
Wilfried RossollMayo Clinic Department of Neuroscience.
Pamela J McLeanMayo Clinic Department of Neuroscience.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Dissecting neuron-microglia-astrocyte interaction in AD pathogenesisRF1AG068581 · NIA · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI PENG, JUNMIN, ROSSOLL, WILFRIED · 2020 to 2023
$5.4M
Mayo Clinic Center for Clinical ProteomicsU01CA271410 · NCI · MAYO CLINIC ROCHESTER · PI Rafael Fonseca, AKHILESH PANDEY · 2022 to 2026
$5.3M
Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALSR01AG077771 · NIA · MAYO CLINIC JACKSONVILLE · PI Wilfried Rossoll, James Shorter · 2023 to 2026
$2.8M
Capturing the molecular complexity of tau pathology-associated proteomes involved in the etiology of Alzheimer's disease and related dementiasRF1AG076122 · NIA · MAYO CLINIC JACKSONVILLE · PI ROSSOLL, WILFRIED · 2022 to 2023
$2.5M
Capturing the molecular complexity of tau pathology-associated proteomes involved in the etiology of Alzheimer's disease and related dementiasR01AG076122 · NIA · MAYO CLINIC JACKSONVILLE · PI Wilfried Rossoll · 2025 to 2026
$1.5M
Dissecting neuron-microglia-astrocyte interaction in AD pathogenesisR01AG068581 · NIA · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI PENG, JUNMIN, ROSSOLL, WILFRIED · 2024 to 2024
$1.2M
NUP50 as a modifier and risk factor for TDP-43 pathology in FTD/ALSR21AG085314 · NIA · MAYO CLINIC JACKSONVILLE · PI ROSSOLL, WILFRIED · 2023 to 2023
$430k
NCI NIH HHS P30 CA015083NCI NIH HHS U01 CA271410NIA NIH HHS R01 AG068581NIA NIH HHS R01 AG076122NIA NIH HHS R01 AG077771NIA NIH HHS R21 AG085314NIA NIH HHS RF1 AG068581NIA NIH HHS RF1 AG076122
6 · The paper itself

Abstract

Lewy pathology can form over decades in patients with Lewy body diseases, but the causal cellular mechanisms associated with this process remain unclear. This project aims to discover proteins that associate with monomeric and/or oligomeric alpha-synuclein during early stages of the aggregation process. To mimic the aggregation processes, cells expressing a synuclein-biotin ligase fusion protein were treated human recombinant pre-formed fibrils and subjected to BioSITe and mass spectrometry. Using a novel split biotin ligase fused to alpha-synuclein facilitated the identification of proteins specifically associated with multimeric alpha-synuclein. A total of 581 proteins were differentiated into potential interactors of monomeric versus multimeric alpha-synuclein in physiological versus aggregated conditions. The data reveal important phosphorylation mechanisms, connections to insulin processing, and a potential interaction with ALS-associated FUS. Interestingly, we identified that loss of specific interactions may contribute to pathology in patients with sporadic onset of Lewy body diseases. Future studies will validate both true interaction of highlighted proteins with alpha-synuclein, and the impact of such proteins on alpha-synuclein aggregation.

Indexed as

alpha-synucleinLewy body diseaseLewy pathologyneurodegenerationproteinopathyproximity proteomics

Identifiers

PMID41282267
PMCPMC12633188

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.